Merck pārtrauc ražot zāles pret C hepatītu Victrelis"
Apskatīt komentārus (0)
06.02.2015
Kā norādīja kompānija, minētais lēmums tika pieņemts uz jaunu ārstniecības līdzekļu ("Sovaldi", "Harvoni" un "Viekira Pak") iznākšanas fona, kura sekas ir pieprasījuma samazināšanās pēc preparāta. Taču, lai pacienti varētu pabeigt 48 nedēļas ilgo ārstēšanās kursu, Victrelis būs pieejams ASV līdz 2015. gada beigām.
**************************
Merck & Co. said it will voluntarily discontinue manufacturing and distributing the hepatitis C therapy Victrelis (boceprevir) in the US by December this year. In a letter posted to the FDA's website, the company noted that the decision was based on "scientific advancement, changes in treatment practices, and the consequent reduction in the demand" for the product in the country.
Merck indicated that the therapy, which was approved by the FDA in 2011, will be supplied to wholesalers from existing inventories through the end of this year to ensure that patients currently using the drug will be able to complete up to 48 weeks of treatment. The drugmaker recommended that doctors do not start new patients on the treatment.
(Read full article at http://www.firstwordpharma.com/node/1258918#axzz3RAXaXEJ8 )
Atpakaļ